{"nctId":"NCT02259088","briefTitle":"A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients","startDateStruct":{"date":"2014-11-05","type":"ACTUAL"},"conditions":["Diabetic Macular Edema","Visual Impairment"],"count":384,"armGroups":[{"label":"Ranibizumab (RFB002)","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab (RFB002)","Procedure: Sham laser"]},{"label":"Laser","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Laser","Drug: Sham injection"]}],"interventions":[{"name":"Ranibizumab (RFB002)","otherNames":["Lucentis"]},{"name":"Laser","otherNames":[]},{"name":"Sham injection","otherNames":[]},{"name":"Sham laser","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female Chinese patients ≥ 18 years of age with diabetes mellitus and with HbA1c ≤10.0%\n* Stable medication for diabetes within 3 months prior to Visit 1\n* Visual impairment due to DME with BCVA score between 78 and 39 letters as measured by ETDRS-like charts at 4 meters\n\nKey Exclusion Criteria:\n\n* Stroke or myocardial infarction less than 3 months prior to screening visit\n* Uncontrolled hypertension\n* Active ocular infection or intraocular inflammation in any eye\n* Treatment with any anti-angiogenic drugs within 3 months prior to baseline visit in any eye\n* Active proliferative diabetic retinopathy in study eye\n* Use of other investigational drugs within 30 days and systemic anti-VEGF drugs within 6 months prior to baseline visit\n* Prior laser photocoagulation or intraocular procedure within 3 months prior to baseline in study eye\n* History of intravitreal corticosteroid treatment in phakic study eye, and in aphakic or pseudophakic within 3 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12","description":"Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. Twelve monthly BCVA values were averaged \\[(Month1+Month2+...+Month12)/12\\], and the baseline BCVA value was subtracted from the average. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"6.58"},{"groupId":"OG001","value":"1.1","spread":"7.73"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in BCVA (Letters) at Each Visit","description":"Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"5.59"},{"groupId":"OG001","value":"-0.9","spread":"5.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"6.44"},{"groupId":"OG001","value":"0.0","spread":"8.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"6.91"},{"groupId":"OG001","value":"1.1","spread":"9.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"7.23"},{"groupId":"OG001","value":"0.0","spread":"11.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"7.41"},{"groupId":"OG001","value":"0.6","spread":"10.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"8.00"},{"groupId":"OG001","value":"0.3","spread":"11.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"7.95"},{"groupId":"OG001","value":"1.3","spread":"10.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"8.12"},{"groupId":"OG001","value":"1.9","spread":"9.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"8.18"},{"groupId":"OG001","value":"1.8","spread":"9.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"8.45"},{"groupId":"OG001","value":"1.6","spread":"9.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"8.55"},{"groupId":"OG001","value":"1.7","spread":"9.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"8.72"},{"groupId":"OG001","value":"2.5","spread":"8.78"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Central Sub-Field Thickness (CSFT) at Each Visit","description":"CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Optical Coherence Tomography (OCT). A negative change value indicates an improvement in macular edema, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-126.7","spread":"140.59"},{"groupId":"OG001","value":"-33.1","spread":"113.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-141.3","spread":"146.15"},{"groupId":"OG001","value":"-48.8","spread":"133.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-154.2","spread":"147.94"},{"groupId":"OG001","value":"-58.5","spread":"157.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-130.4","spread":"152.60"},{"groupId":"OG001","value":"-72.6","spread":"149.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-141.0","spread":"153.28"},{"groupId":"OG001","value":"-72.3","spread":"150.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-146.2","spread":"154.87"},{"groupId":"OG001","value":"-72.9","spread":"152.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-138.4","spread":"161.04"},{"groupId":"OG001","value":"-72.4","spread":"150.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-146.9","spread":"154.68"},{"groupId":"OG001","value":"-81.8","spread":"151.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-142.4","spread":"156.03"},{"groupId":"OG001","value":"-80.9","spread":"157.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-137.6","spread":"152.73"},{"groupId":"OG001","value":"-82.9","spread":"166.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-144.8","spread":"159.87"},{"groupId":"OG001","value":"-88.1","spread":"170.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-146.5","spread":"157.61"},{"groupId":"OG001","value":"-85.9","spread":"166.60"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With BCVA Gain of ≥ 10 and ≥ 15 Letters From Baseline at Month 12","description":"Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With BCVA Loss of < 10 and < 15 Letters From Baseline to Month 12","description":"Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"89.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With BCVA ≥ 73 Letters at Month 12","description":"Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. BCVA ≥ 73 letters is approximately equivalent to 20/40 on a Snellen chart. One eye (study eye) contributed to the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":null},{"groupId":"OG001","value":"21.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Average Change in BCVA From Month 4 to Month 12 Compared to Month 3","description":"Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. Nine monthly BCVA values were averaged \\[(Month4+Month5+...+Month12)/9\\],and the Month 3 BCVA value was subtracted from the average. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":"10.66"},{"groupId":"OG001","value":"59.2","spread":"12.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"4.51"},{"groupId":"OG001","value":"0.2","spread":"6.08"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Visual Functioning at Month 6 and Month 12, Composite Score","description":"Visual functioning was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in visual functioning, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"13.54"},{"groupId":"OG001","value":"0.5","spread":"13.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"14.99"},{"groupId":"OG001","value":"-0.4","spread":"15.89"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported General Health at Month 6 and Month 12","description":"General health was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in general health, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"22.32"},{"groupId":"OG001","value":"-0.4","spread":"21.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"24.34"},{"groupId":"OG001","value":"-4.3","spread":"26.56"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported General Vision at Month 6 and Month 12","description":"General vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in general vision, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"18.77"},{"groupId":"OG001","value":"4.7","spread":"19.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"18.12"},{"groupId":"OG001","value":"5.9","spread":"20.06"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Color Vision at Month 6 and Month 12","description":"Color vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in color vision, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"16.68"},{"groupId":"OG001","value":"2.2","spread":"17.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"21.55"},{"groupId":"OG001","value":"1.6","spread":"20.35"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Peripheral Vision at Month 6 and Month 12","description":"Peripheral vision was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in peripheral vision, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"20.51"},{"groupId":"OG001","value":"5.5","spread":"22.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"25.07"},{"groupId":"OG001","value":"3.1","spread":"27.64"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Ocular Pain at Month 6 and Month 12","description":"Ocular pain was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in ocular pain, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"20.71"},{"groupId":"OG001","value":"1.5","spread":"20.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"19.89"},{"groupId":"OG001","value":"4.1","spread":"22.72"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Near Activities at Month 6 and Month 12","description":"Near activities were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in near activities, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"23.81"},{"groupId":"OG001","value":"-1.7","spread":"24.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"24.64"},{"groupId":"OG001","value":"-3.4","spread":"21.93"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Distance Activities at Month 6 and Month 12","description":"Distance activities were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in distance activities, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"20.79"},{"groupId":"OG001","value":"-2.8","spread":"19.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"23.74"},{"groupId":"OG001","value":"-5.5","spread":"21.89"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Social Functioning at Month 6 and Month 12","description":"Social functioning was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in social functioning, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"19.24"},{"groupId":"OG001","value":"-1.5","spread":"15.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"21.58"},{"groupId":"OG001","value":"-3.2","spread":"18.51"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Mental Health at Month 6 and Month 12","description":"Mental health was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in mental health, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"23.07"},{"groupId":"OG001","value":"-0.2","spread":"23.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"25.05"},{"groupId":"OG001","value":"0.6","spread":"23.32"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Roles Difficulties at Month 6 and Month 12","description":"Roles difficulties were assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in roles difficulties, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"27.05"},{"groupId":"OG001","value":"-0.4","spread":"24.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"27.62"},{"groupId":"OG001","value":"-1.4","spread":"28.36"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Dependency at Month 6 and Month 12","description":"Dependency was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in dependency, while a negative change value indicates a worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"27.95"},{"groupId":"OG001","value":"-4.3","spread":"27.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"30.47"},{"groupId":"OG001","value":"-5.3","spread":"27.87"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Patient-Reported Driving at Month 6 and Month 12","description":"Driving was assessed by the patient using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) on a scale from 0 to 100, where 0 = worst possible score and 100 = best. A positive change value indicates a perceived improvement in driving, while a negative change value indicates a worsening. Note: Many patients did not answer the driving related question as they did not drive at all.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"15.87"},{"groupId":"OG001","value":"2.8","spread":"20.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"12.29"},{"groupId":"OG001","value":"4.5","spread":"27.98"}]}]}]},{"type":"SECONDARY","title":"Mean Number of Ranibizumab Re-treatments Received in the Study Eye From Month 3 Onward","description":"A ranibizumab re-treatment was defined as an administration of ranibizumab injection at a scheduled visit following at least one non-missed visit where ranibizumab was not administered in the study eye due to visual acuity stabilization. This outcome measure was pre-specified for the Ranibizumab 0.5 mg arm only.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.64"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":57,"n":307},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Hypertension","Cough","Urinary tract infection"]}}}